Induction of DNA Damage-Inducible Gene Gadd45 Beta Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
Resource
CANCER RESEARCH v.70 n.22 pp.9309-9318
Journal
CANCER RESEARCH
Journal Volume
v.70
Journal Issue
n.22
Pages
9309-9318
Date Issued
2010
Date
2010
Author(s)
OU DA-LIANG
SHEN YING-CHUN
YU SUNG-LIANG
CHEN KUEN-FENG
YEH PEI-YEN
LIN LIANG-IN
HSU CHIUN
CHENG ANN-LII
Abstract
Markers that could accurately predict responses to the general kinase inhibitor sorafenib are needed to better leverage its clinical applications. In this study, we examined a hypothesized role in the drug response for the growth arrest DNA damage-inducible gene 45 beta (GADD45 beta ), which is commonly underexpressed in hepatocellular carcinoma (HCC) where sorafenib may offer an important new therapeutic option. The anticancer activity of sorafenib- induced GADD45 beta expression was tested in a panel of HCC cell lines and xenograft models. We found that GADD45 beta mRNA and protein expression were induced relatively more prominently in HCC cells that were biologically sensitive to sorafenib treatment. GADD45 beta induction was not found after treatment with either the mitogen-activated protein kinase-extracellular signal-regulated kinase (ERK) kinase ( MEK) inhibitor U0126 or the Raf inhibitor ZM336372, suggesting that GADD45 beta induction by sorafenib was independent of Raf/ MEK/ERK signaling activity. However, c- Jun NH2-terminal kinase (JNK) kinase activation occurred preferentially in sorafenib-sensitive cells. Small interfering RNA-mediated knockdown of GADD45 beta or JNK kinase limited the proapoptotic effects of sorafenib in sorafenib-sensitive cells . We defined the -339/-267 region in the GADD45 beta promoter containing activator protein-1 and SP1-binding sites as a crucial region for GADD45 beta induction by sorafenib. Together, our findings suggest that GADD45 beta induction contributes to sorafenib-induced apoptosis in HCC cells, prompting further studies to validate its potential value in predicting sorafenib efficacy.
SDGs